Faecal gas analysis by electronic nose as novel, non-invasive method for assessment of active and quiescent paediatric inflammatory bowel disease: Proof of principle study
- 1 September 2014
- journal article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
Abstract
Inflammatory bowel disease (IBD) and its two phenotypes ulcerative colitis (UC) and Crohn's disease (CD) are essentially assessed by endoscopy, both in initial diagnostic work-up and during follow-up. This carries a high burden, especially on paediatric patients. Faecal volatile organic compounds (VOCs) are considered potential non-invasive biomarkers for intestinal diseases linked to gut microbiota alterations. We hypothesized that faecal VOC analysis by electronic nose allows discrimination of children with CD, UC and controls during active disease and remission. Faecal VOC patterns of children with newly diagnosed IBD and controls were studied by an electronic nose (Cyranose 320®), at baseline and upon achieving remission at 6-weeks of follow-up. Disease activity was assessed by global physician's assessment, substantiated by serum C-reactive protein and faecal calprotectin. Internally cross-validated receiver-operator-characteristic curves and corresponding sensitivity and specificity for detection of IBD were calculated RESULTS: Faecal VOC profiles of patients with UC (26) and CD (29) differed from controls (28); in active disease (AUC±95% CI, p-value, sensitivity, specificity: 1.00±0.00; p<0.001, 100%, 100%) and (0.85±0.05, p<0.001, 86%, 67%) and in clinical remission (0.94±0.06, p<0.001, 94%, 94%) and (0.94±0.06, p<0.001, 94%, 94%), respectively. Furthermore, CD-patients differed from UC-patients during active disease (0.96±0.03; p<0.001, 97%, 92%), and upon achieving clinical remission (0.81±0.08, p=0.002, 88%, 72%). Faecal VOC analysis allowed discrimination of paediatric patients with IBD from controls, both during active disease and remission. It therefore has potential as non-invasive test, in both diagnostic work-up and assessment of disease activity in IBD.Keywords
Funding Information
- Falk Benelux BV (8717)
This publication has 29 references indexed in Scilit:
- Rising incidence of pediatric inflammatory bowel disease in Scotland*Inflammatory Bowel Diseases, 2012
- Role of the microbiota in inflammatory bowel diseasesInflammatory Bowel Diseases, 2012
- Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic ReviewGastroenterology, 2012
- Fecal Calprotectin Is a Useful Marker for Disease Activity in Pediatric Patients with Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2011
- Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trendsInflammatory Bowel Diseases, 2011
- Microbiota in Pediatric Inflammatory Bowel DiseaseThe Journal of Pediatrics, 2010
- Rising Incidence of Inflammatory Bowel Disease Among Children: A 12‐year StudyJournal of Pediatric Gastroenterology and Nutrition, 2010
- Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel diseaseDigestive and Liver Disease, 2008
- Laboratory markers in IBD: useful, magic, or unnecessary toys?Gut, 2006
- Technology Insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel diseaseNature Clinical Practice Gastroenterology & Hepatology, 2005